Asia Pacific Electronic Clinical Outcome Assessment Markets, 2019-2020 & 2021-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Electronic Clinical Outcome Assessment Market By Delivery Mode, By End Use, By Country, Industry Analysis and Forecast, 2020 – 2026” report has been added to ResearchAndMarkets.com’s offering.

The Asia Pacific Electronic Clinical Outcome Assessment Solution Market (eCOA)is expected to witness market growth of 20.6% CAGR during the forecast period (2020-2026).

The China market dominated the Asia Pacific Pharma & Biotech Companies Market by Country in 2019, thereby, achieving a market value of $17.1 Million by 2026.

The Japan market is exhibiting a CAGR of 21.9% during (2020 – 2026).

Additionally, The India market is anticipated to witness a CAGR of 22.7% during (2020 – 2026).

With an aim to gather patient data in a clinical trial, an eCOA solution is utilized. The global electronic clinical outcome assessment (eCOA) solutions market is anticipated to witness consistent & high growth over the forecast years. Some aspects including a wide consumer base globally, increasing public-private funding for clinical researchers, high regulatory compliance across industrial researchers, growing requirement for enhanced data centralization & collection for early regulatory approval are anticipated to open growth avenues for the eCOA market.

The leading players operating in the market are expected to witness various growth possibilities due to many factors such as increasing number of clinical research around developing economies, rising outsourcing of research activities by pharma companies, and changing preference from manual data interpretation to real-time data analysis. On the flip side, the growth of the eCOA market is expected to be hampered due to the high cost of installation & scarcity of skilled professionals of accurate data interpretation.

The market growth is expected to be driven by some significant aspects including high R&D investments by the pharma giants, increasing demand for clinical trials in developing markets, and a rising number of diseases. Also, the paradigm shift from manual data interpretation to real-time data analysis is expected to also support the growth of the eCOA market.

In addition to it, regulatory bodies are putting a high emphasis on assessing wider properties of patient well-being in order to enhance the overall well-being. Hence, clinical outcome assessments (COAs) are constantly utilized to evaluate the treatments’ influence on several chronic diseases, and in some cases, these have a considerable role in the regulatory approval of drugs. Although, the major restraints for the market growth are the huge cost of implementation & data privacy concerns.

Scope of the Study

Market Segments covered in the Report:

By Delivery Mode

• Web-hosted eCOA
• Cloud-based eCOA
• Licensed enterprises eCOA

By End Use

• Contract Research Organizations (CROs)
• Hospitals
• Academic Institutes
• Pharma & Biotech Companies
• Medical Device Manufacturers

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled

• Oracle Corporation
• Dassault Systemes SE
• IQVIA Holdings, Inc.
• Parexel International Corporation (Pamplona Capital Management)
• IBM Corporation (Merge Healthcare)
• Signant Health
• ERT Clinical
• eClinical Solutions LLC
• Castor EDC
• Anju Software, Inc. (OmniComm Systems)

For more information about this report visit https://www.researchandmarkets.com/r/3fdqp8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900